SequelSEC

Erasca, Inc. ERAS

Pharmaceutical Preparations · CIK 0001761918 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$140.90M
Fiscal year ended 2025-12-31
Free cash flow
-$95.58M
Fiscal year ended 2025-12-31

Erasca, Inc. (ERAS) reported net income of -$124.55M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Erasca, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Erasca, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$140.90M-$179.59M-$141.52M-$247.45M-$124.88M-$109.25M
Net income-$124.55M-$161.65M-$125.04M-$242.80M-$122.76M-$101.66M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 283.53Mshares 233.82Mshares 150.18Mshares 122.02Mshares 66.29MUnavailable
Pretax income-$124.55M-$161.65MUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0UnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.44$-0.69$-0.83$-1.99$-1.85Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$38.55M$41.73M$37.70M$32.99M$22.62M$7.96M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Erasca, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$73.80M$67.74M$93.08M$284.22M$360.49M$65.38M
Total assets$396.15M$502.53M$395.30M$514.91M$501.42M$124.82M
Current assets$286.24M$308.79M$320.68M$444.50M$420.02M$119.99M
Total liabilities$70.98M$79.03M$78.61M$103.06M$44.89M$17.40M
Current liabilities$28.51M$31.40M$26.16M$48.69M$26.22M$13.68M
Total equity incl. NCI$325.17M$423.50M$316.69M$411.85M$456.53M-$113.98M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$981.00K$468.00K$2.00M$23.05M$4.68M$878.00K

Cash flow

Erasca, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$95.46M-$109.42M-$101.22M-$103.26M-$79.60M-$32.69M
Capital expenditures$128.00K$60.00K$1.78M$14.55M$11.20M$947.00K
Investing cash flow$100.42M-$156.62M-$91.22M-$71.08M-$64.59M-$71.20M
Financing cash flow$1.10M$240.70M$1.30M$98.08M$439.40M$139.99M
Net change in cash$6.07M-$25.34M-$191.14M-$76.27M$295.21M$36.10M
Stock-based compensation$24.90M$26.97M$26.23M$20.11M$8.33M$797.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$3.11M$3.80M$3.73M$2.64M$829.00K$540.00K

Derived

Erasca, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$95.58M-$109.48M-$102.99M-$117.82M-$90.80M-$33.63M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio10.04x9.84x12.26x9.13x16.02x8.77x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ERAS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2020-12-31

Difference 221405000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.